

Neurology Order Form

Fax Completed Form To:

Phone:



| PATIENT INFORMATION | | |
|-----------------------------|--------------------------------------|---|
| Patient Name: | Date of Birth: | Referral Date: |
| Address: | | City/State/Zip: |
| Home Phone: | Cell Phone: | Work Phone: |
| Secondary Contact: | Height: Weight: | <input type="checkbox"/> Male <input type="checkbox"/> Female |
| Patient Diagnosis & ICD-10: | | |
| Allergies: | | |

| PROVIDER INFORMATION | | |
|--|--------|-----------------|
| Physician Name: | Lic.#: | DEA #: |
| Practice Name: | NPI#: | |
| Address: | | City/State/Zip: |
| Office Contact: | Phone: | Fax: |
| Supervisory Physician (if applicable): | | |

| PLEASE ATTACH | |
|---|---|
| <input type="checkbox"/> Patient demographics & front/back copy of all insurance cards (prescription & medical) | <input type="checkbox"/> Vaccine status (any vaccination) and documentation of any recent vaccinations |
| <input type="checkbox"/> Recent office visit notes, history & physical, lab & pertinent procedure results | <input type="checkbox"/> HBV lab results within last 12 months (<i>Uplizna only</i>) |
| <input type="checkbox"/> Current medication list & list of prior medications tried and failed (with dates) | <input type="checkbox"/> Date of diagnosis, current FVC%, ALSFRS-R score, and JourneyMate form (<i>Radicava only</i>) |
| <input type="checkbox"/> Line access documentation/verification if applicable | <input type="checkbox"/> Anti-acetylcholine receptor (AChR) antibody positive results (<i>Vyvgart</i>) |
| <input type="checkbox"/> Quantitative serum Immunoglobulin lab results (<i>Uplizna only</i>) | <input type="checkbox"/> Letter of medical necessity if drug dosing or indication is outside of FDA guidelines |
| <input type="checkbox"/> TB lab results within last 12 months (<i>Uplizna only</i>) | |

| NURSING & LAB ORDERS |
|---|
| Nurse Orders: Nurse to provide assessment, teaching, lab draws, medication administration and vascular access device insertion and/or management per physician orders. |
| Flush Orders: NaCl 0.9% - 5-10mL flush pre and post infusion and as needed Heparin - <input type="checkbox"/> 10units/mL ---OR--- <input type="checkbox"/> 100units/mL - 3-5mL flush after post-infusion NS flush if indicated to maintain line |
| Lab Orders: Lab Date & Frequency: |

| PRESCRIPTION ORDERS | | |
|---|--|--|
| Anaphylaxis Kit: (Check all that apply) | <input type="checkbox"/> Epinephrine 0.3mg IM as needed | <input type="checkbox"/> Solu-cortef 250mg-500mg IV as needed |
| | <input type="checkbox"/> Diphenhydramine _____mg IV as needed | <input type="checkbox"/> Solu-Medrol 60mg - 125mg IV as needed |
| | <input type="checkbox"/> NS Hydration 500 ml IV over 30 minutes as needed | <input type="checkbox"/> Other _____ |
| Pre-Medications: (Check all that apply) | <input type="checkbox"/> Acetaminophen _____mg PO _____minutes prior to infusion | <input type="checkbox"/> Solu-Medrol _____mg IV _____minutes prior to infusion |
| | <input type="checkbox"/> Diphenhydramine _____mg <input type="checkbox"/> PO ---OR--- <input type="checkbox"/> IV _____minutes prior to infusion | <input type="checkbox"/> Other _____ |
| Supply Orders: All supplies for vascular access line care, drug administration kit(s), pump, and IV pole will be provided as necessary | | |

| PRODUCT | PRESCRIPTION INFORMATION | REFILLS |
|--|--|---------|
| Is this a first dose? <input type="checkbox"/> Yes <input type="checkbox"/> No If No, when was last dose given? _____ When is patient due for next dose? _____ | | |
| <input type="checkbox"/> KINSULA | <input type="checkbox"/> Induction: 700mg IV infusion via <input type="checkbox"/> gravity ---OR--- <input type="checkbox"/> pump over 30 minutes every 4 weeks x 3 doses <input type="checkbox"/> Maintenance: 1400mg IV infusion via <input type="checkbox"/> gravity ---OR--- <input type="checkbox"/> pump over 30 minutes every 4 weeks <input type="checkbox"/> If missed dose, administer the same dose as soon as possible and continue every 4 weeks | NONE |
| <input type="checkbox"/> RADICAVA | <input type="checkbox"/> Induction: 60mg IV infusion via <input type="checkbox"/> gravity ---OR--- <input type="checkbox"/> pump over 1 hour daily for 14 days followed by 14 day drug-free period <input type="checkbox"/> Maintenance: 60mg IV infusion via <input type="checkbox"/> gravity ---OR--- <input type="checkbox"/> pump over 1 hour daily for 10 days out of 14 day period followed by 14 day drug-free periods | NONE |
| <input type="checkbox"/> UPLIZNA | <input type="checkbox"/> Induction: 300mg IV infusion via <input type="checkbox"/> gravity ---OR--- <input type="checkbox"/> pump over approximately 90 minutes at 0 and 2 weeks and <i>CBC lab testing every _____ months</i> <input type="checkbox"/> Maintenance: (<i>starting 6 months from first infusion</i>) 300mg IV infusion via <input type="checkbox"/> gravity ---OR--- <input type="checkbox"/> pump over approximately 90 minutes every 6 months | NONE |
| <input type="checkbox"/> VYEPTI | <input type="checkbox"/> 100mg IV infusion via <input type="checkbox"/> gravity ---OR--- <input type="checkbox"/> pump over approximately 30 minutes every 12 weeks <input type="checkbox"/> 300mg IV infusion via <input type="checkbox"/> gravity ---OR--- <input type="checkbox"/> pump over approximately 30 minutes every 12 weeks | |
| <input type="checkbox"/> VYVGART | 10mg/kg IV infusion via <input type="checkbox"/> gravity ---OR--- ---OR--- pump over at least 1 hour once every week for 4 weeks <i>*Up to max of 1200mg for patient weight of 120kg+ (Total volume is 125ml in NS solution)</i> Administer additional treatment cycles <input type="checkbox"/> every 50 days ---OR--- <input type="checkbox"/> Prescriber to evaluate treatment cycle frequency after completion of initial treatment cycle According to the Package Insert: Administer subsequent treatment cycles based on clinical evaluation; the safety of initiating subsequent cycles sooner than 50 days from the start of the previous treatment cycle has not been established. | |
| <input type="checkbox"/> VYVGART HYTRULO | 1,008mg/11,200 units subcutaneous injection over approximately 30 to 90 seconds in cycles of once weekly injections for 4 weeks Administer additional treatment cycles <input type="checkbox"/> every 50 days ---OR--- <input type="checkbox"/> Prescriber to evaluate treatment cycle frequency after completion of initial treatment cycle According to the Package Insert: Administer subsequent treatment cycles based on clinical evaluation; the safety of initiating subsequent cycles sooner than 50 days from the start of the previous treatment cycle has not been established. | |
| <input type="checkbox"/> IG | Refer to Immunoglobulin Form | |
| <input type="checkbox"/> SOLIRIS/ULTOMIRIS | Refer to Soliris or Ultomiris Order Form | |
| <input type="checkbox"/> OTHER | | NONE |

By signing this form and utilizing our services, you are authorizing Amerita to serve as your prior authorization designated agent in dealing with medical and prescription insurance companies.

| | | | | | |
|------------------------|------------|------|------------------------|------------|------|
| Prescriber's Signature | Print Name | Date | Prescriber's Signature | Print Name | Date |
| Dispense as Written | | | Substitution Permitted | | |

